Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

被引：0

作者：

L S Steelman

S L Abrams

J Whelan

F E Bertrand

D E Ludwig

J Bäsecke

M Libra

F Stivala

M Milella

A Tafuri

P Lunghi

A Bonati

A M Martelli

J A McCubrey

机构：

[1] Brody School of Medicine,Department of Microbiology and Immunology

[2] East Carolina University,Division of Hematology and Oncology, Department of Medicine

[3] ImClone Systems,Department of Biomedical Sciences

[4] Georg-August University,Department of Cellular Biotechnology and Hematology

[5] University of Catania,Department of Clinical Sciences

[6] Regina Elena Cancer Center,Department of Human Anatomical Sciences

[7] University La Sapienza of Rome,undefined

[8] University of Parma,undefined

[9] Unit of Hematology and Bone-Marrow Transplantation,undefined

[10] University Hospital of Parma,undefined

[11] University of Bologna,undefined

[12] IGM-CNR,undefined

[13] c/o IOR,undefined

来源：

Leukemia | 2008年 / 22卷

关键词：

Raf; PI3K; Akt; signal transduction; inhibitors; chemotherapeutic drugs;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Mutations and chromosomal translocations occur in leukemic cells that result in elevated expression or constitutive activation of various growth factor receptors and downstream kinases. The Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways are often activated by mutations in upstream genes. The Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways are regulated by upstream Ras that is frequently mutated in human cancer. Recently, it has been observed that the FLT-3 and Jak kinases and the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) phosphatase are also frequently mutated or their expression is altered in certain hematopoietic neoplasms. Many of the events elicited by the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways have direct effects on survival pathways. Aberrant regulation of the survival pathways can contribute to uncontrolled cell growth and lead to leukemia. In this review, we describe the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT signaling cascades and summarize recent data regarding the regulation and mutation status of these pathways and their involvement in leukemia.

引用

页码：686 / 707

页数：21

共 50 条

[1] Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S.
Abrams, S. L.
Whelan, J.
Bertrand, F. E.
Ludwig, D. E.
Baesecke, J.
Libra, M.
Stivala, F.
Milella, M.
Tafuri, A.
Lunghi, P.
Bonati, A.
Martelli, A. M.
McCubrey, J. A.
LEUKEMIA, 2008, 22 (04) : 686 - 707
[2] Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
J A McCubrey
L S Steelman
S L Abrams
F E Bertrand
D E Ludwig
J Bäsecke
M Libra
F Stivala
M Milella
A Tafuri
P Lunghi
A Bonati
A M Martelli
Leukemia, 2008, 22 : 708 - 722
[3] Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
McCubrey, J. A.
Steelman, L. S.
Abrams, S. L.
Bertrand, F. E.
Ludwig, D. E.
Baesecke, J.
Libra, M.
Stivala, F.
Milella, M.
Tafuri, A.
Lunghi, P.
Bonati, A.
Martelli, A. M.
LEUKEMIA, 2008, 22 (04) : 708 - 722
[4] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Qingfang Li
Zhihui Li
Ting Luo
Huashan Shi
Molecular Biomedicine, 3
[5] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Qingfang
Li, Zhihui
Luo, Ting
Shi, Huashan
MOLECULAR BIOMEDICINE, 2022, 3 (01):
[6] Therapeutic Resistance Resulting From Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathways
McCubrey, James A.
Steelman, Linda S.
Kempf, C. Ruth
Chappell, William H.
Abrams, Stephen L.
Stivala, Franca
Malaponte, Graziella
Nicoletti, Ferdinando
Libra, Massimo
Baesecke, Joerg
Maksimovic-Ivanic, Danijela
Mijatovic, Sanja
Montalto, Giuseppe
Cervello, Melchiorre
Cocco, Lucio
Martelli, Alberto M.
JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (11) : 2762 - 2781
[7] Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, Kamal S.
Loi, Sherene
de Azambuja, Evandro
Metzger-Filho, Otto
Saini, Monika Lamba
Ignatiadis, Michail
Dancey, Janet E.
Piccart-Gebhart, Martine J.
CANCER TREATMENT REVIEWS, 2013, 39 (08) : 935 - 946
[8] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
Chappell, William H.
Steelman, Linda S.
Long, Jacquelyn M.
Kempf, Ruth C.
Abrams, Stephen L.
Franklin, Richard A.
Baesecke, Joerg
Stivala, Franca
Donia, Marco
Fagone, Paolo
Malaponte, Graziella
Mazzarino, Maria C.
Nicoletti, Ferdinando
Libra, Massimo
Maksimovic-Ivanic, Danijela
Mijatovic, Sanja
Montalto, Giuseppe
Cervello, Melchiorre
Laidler, Piotr
Milella, Michele
Tafuri, Agostino
Bonati, Antonio
Evangelisti, Camilla
Cocco, Lucio
Martelli, Alberto M.
McCubrey, James A.
ONCOTARGET, 2011, 2 (03) : 135 - 164
[9] Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
McCubrey, James A.
Steelman, Linda S.
Abrams, Steven L.
Lee, John T.
Chang, Fumin
Bertrand, Fred E.
Navolanic, Patrick M.
Terrian, David M.
Franklin, Richard A.
D'Assoro, Antonio B.
Salisbury, Jeffrey L.
Mazzarino, Maria Clorinda
Stivala, Franca
Libra, Massimo
ADVANCES IN ENZYME REGULATION, VOL 46, PROCEEDINGS, 2006, 46 : 249 - 279
[10] Effect of everolimus and gefitinib on PI3K/akt/mTOR and raf/MEK/ERK pathways in NSCLC cells.
Dong, S.
Zhang, X.
Chang, H.
Guo, A.
Zhu, J.
Yang, S.
Wu, Y.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →